

Juan Marcos González

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4974380/publications.pdf>

Version: 2024-02-01

66
papers

1,583
citations

567281

15
h-index

315739

38
g-index

67
all docs

67
docs citations

67
times ranked

2236
citing authors

#	ARTICLE	IF	CITATIONS
1	Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. <i>Value in Health</i> , 2016, 19, 300-315.	0.3	782
2	Incorporating patient-preference evidence into regulatory decision making. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 2984-2993.	2.4	182
3	A Guide to Measuring and Interpreting Attribute Importance. <i>Patient</i> , 2019, 12, 287-295.	2.7	62
4	Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2013, 7, 937.	1.8	42
5	Effects of interactions between solids and surfactants on the tribological properties of water-based drilling fluids. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2011, 391, 216-223.	4.7	35
6	Patient Preferences Around Extent of Surgery in Low-Risk Thyroid Cancer: A Discrete Choice Experiment. <i>Thyroid</i> , 2020, 30, 1044-1052.	4.5	35
7	The value to patients of reducing lesion severity in plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2011, 22, 266-275.	2.2	27
8	Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment. <i>British Journal of Dermatology</i> , 2017, 176, 777-785.	1.5	26
9	Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. <i>Value in Health</i> , 2022, 25, 685-694.	0.3	23
10	Physicians' Preferences for Bone Metastases Drug Therapy in the United States. <i>Value in Health</i> , 2015, 18, 78-83.	0.3	22
11	What are people willing to pay for whole-genome sequencing information, and who decides what they receive?. <i>Genetics in Medicine</i> , 2016, 18, 1295-1302.	2.4	21
12	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567.	1.4	21
13	Patient preferences for treatments to delay bone metastases. <i>Prostate</i> , 2014, 74, 1488-1497.	2.3	20
14	Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. <i>Value in Health</i> , 2017, 20, 32-39.	0.3	19
15	Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation—evidence from the United States and Japan. <i>Value in Health Regional Issues</i> , 2015, 6, 65-72.	1.2	18
16	A Joint Estimation Method to Combine Dichotomous Choice CVM Models with Count Data TCM Models Corrected for Truncation and Endogenous Stratification. <i>Journal of Agricultural & Applied Economics</i> , 2008, 40, 681-695.	1.4	16
17	Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). <i>Patient Preference and Adherence</i> , 2011, 5, 307.	1.8	15
18	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. <i>Cancer Management and Research</i> , 2017, Volume 9, 149-158.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis. <i>Patient</i> , 2018, 11, 285-300.	2.7	15
20	Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment. <i>Pharmacoeconomics</i> , 2018, 36, 973-986.	3.3	15
21	Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments. <i>Journal of Thyroid Research</i> , 2015, 2015, 1-8.	1.3	14
22	Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008051.	3.9	14
23	Surgical treatment for recurrent shoulder instability: factors influencing surgeon decision making. <i>Journal of Shoulder and Elbow Surgery</i> , 2021, 30, e85-e102.	2.6	14
24	Quantifying Value of Hope. <i>Value in Health</i> , 2021, 24, 1511-1519.	0.3	13
25	Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). <i>Contemporary Clinical Trials</i> , 2019, 76, 120-131.	1.8	12
26	Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. <i>Patient</i> , 2016, 9, 323-333.	2.7	11
27	Patient Preferences for Surgical Treatment of Knee Osteoarthritis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 2022-2031.	3.0	10
28	What is a Good Death? A Choice Experiment on Care Indicators for Patients at End of Life. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 457-467.	1.2	10
29	Trading Health Risks for Glory: A Reformulation of the Goldman Dilemma. <i>Sports Medicine</i> , 2018, 48, 1963-1969.	6.5	7
30	Symposium Title: Preference Evidence for Regulatory Decisions. <i>Patient</i> , 2018, 11, 467-473.	2.7	7
31	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008797.	3.9	7
32	Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. <i>Annals of Surgical Oncology</i> , 2016, 23, 3510-3517.	1.5	6
33	The Impact of the Risk Functional Form Assumptions on Maximum Acceptable Risk Measures. <i>Patient</i> , 2021, 14, 827-836.	2.7	6
34	Patients' and physicians' risk-benefit trade-off preferences for metastatic colorectal cancer treatments. <i>Journal of Clinical Oncology</i> , 2015, 33, 3591-3591.	1.6	6
35	Who Would Pay Higher Taxes for Better Mental Health? Results of a Large-Sample National Choice Experiment. <i>Milbank Quarterly</i> , 2021, 99, 771-793.	4.4	5
36	Parental Preferences for Vesicoureteral Reflux Treatment: A Crowd-sourced, Best-worst Scaling Study. <i>Urology</i> , 2019, 128, 71-77.	1.0	4

#	ARTICLE	IF	CITATIONS
37	<p><p>Why Do People Living with HIV Adhere to Antiretroviral Therapy and Not Comorbid Cardiovascular Disease Medications? A Qualitative Inquiry</p>. Patient Preference and Adherence, 2020, Volume 14, 985-994.</p>	1.8	4
38	<p>Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. JCO Oncology Practice, 2021, 17, e1639-e1648.</p>	2.9	4
39	<p>Do Patient Preferences Align With Value Frameworks? A Discrete-Choice Experiment of Patients With Breast Cancer. MDM Policy and Practice, 2020, 5, 238146832092801.</p>	0.9	3
40	<p>Primary Immune Deficiency: Patients's Preferences for Replacement Immunoglobulin Therapy. Frontiers in Immunology, 2022, 13, 827305.</p>	4.8	3
41	<p>Patient And Physician Preferences In The United States For Benefits And Risks Of Anticoagulant Use In Atrial Fibrillation " Results From A Conjoint-Analysis Study. Value in Health, 2013, 16, A11.</p>	0.3	2
42	<p>Estimating conditional certainty equivalents using choice-experiment data. Journal of Choice Modelling, 2015, 15, 14-25.</p>	2.3	2
43	<p>Incomplete information and irrelevant attributes in stated preference values for health interventions. Health Economics (United Kingdom), 2021, 30, 2637-2648.</p>	1.7	2
44	<p>The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecologic Oncology, 2021, 162, 440-446.</p>	1.4	2
45	<p>PMC29 PATIENT PREFERENCE WEIGHTS FOR BENEFIT-RISK ANALYSIS: A STATIN CASE STUDY. Value in Health, 2010, 13, A19.</p>	0.3	1
46	<p>PND36 Structured Benefit-Risk Assessment of Triptan Treatments Using Patient-Preference Data. Value in Health, 2012, 15, A147.</p>	0.3	1
47	<p>Patients at the Center of Regulatory Decisions: Using Stated-Preference Data to Help Regulators Answer Difficult Questions. Value in Health, 2013, 16, A387.</p>	0.3	1
48	<p>Heterogeneity in Parent Preferences for Peanut Desensitization Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3459-3465.</p>	3.8	1
49	<p>UT3 HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS. Value in Health, 2009, 12, A224.</p>	0.3	0
50	<p>PSY48 THE VALUE TO PATIENTS OF TREATING PLAQUE PSORIASIS. Value in Health, 2010, 13, A214-A215.</p>	0.3	0
51	<p>BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT. Value in Health, 2010, 13, A243.</p>	0.3	0
52	<p>PMS50 PATIENTS' STATED HEALTH-OUTCOME PREFERENCES FOR CONFOUNDED PATIENT-REPORTED OUTCOME DOMAINS FOR OSTEOARTHRITIS. Value in Health, 2010, 13, A312.</p>	0.3	0
53	<p>PMS52 PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH THE USE OF NSAIDS: EVIDENCE FROM PATIENTS DIAGNOSED WITH OSTEOARTHRITIS (OA) IN UK. Value in Health, 2010, 13, A312.</p>	0.3	0
54	<p>PMS68 PHYSICIANS' STATED PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH NSAID USE IN PATIENTS WITH OSTEOARTHRITIS IN UNITED KINGDOM. Value in Health, 2010, 13, A316.</p>	0.3	0

#	ARTICLE	IF	CITATIONS
55	PDB58 How Much Do Patients with Type 2 Diabetes Value Improvements in Dosing Convenience? Results from a Conjoint Study. Value in Health, 2011, 14, A482.	0.3	0
56	PSY38 Estimating Healthy-Time Equivalents for Migraine Treatment Outcomes from Conjoint Analysis Measures of Patient Preferences. Value in Health, 2011, 14, A417.	0.3	0
57	PMS46 Patient Trade-Offs Between Frequency and Duration of Biologic Treatments for Rheumatoid Arthritis. Value in Health, 2012, 15, A42.	0.3	0
58	Stated time-allocation, adherence, and health-outcome tradeoff preferences in cystic fibrosis households. Value in Health, 2013, 16, A26.	0.3	0
59	Psoriasis Patients'™ Tolerance for Therapeutic Risks in Return for Symptom Improvement in the United Kingdom. Value in Health, 2013, 16, A508.	0.3	0
60	Physicians'™ Preferences for Bone Metastases Treatments in Canada. Value in Health, 2014, 17, A93.	0.3	0
61	What are people willing to pay for whole genome sequencing information?. Value in Health, 2015, 18, A285-A286.	0.3	0
62	Patients'™ And Physicians'™ Time Trade-Off Preferences For Adverse Outcomes Associated With Metastatic Colorectal Cancer Treatments. Value in Health, 2015, 18, A9.	0.3	0
63	Patient Preferences for Health States Following Alternative Management Options for Ductal Carcinoma in Situ. Value in Health, 2018, 21, S11-S12.	0.3	0
64	Parental preferences for vesicoureteral reflux treatment: Profile case best-worst scaling. Journal of Pediatric Urology, 2021, 17, 86.e1-86.e9.	1.1	0
65	Stratified psoriasis treatment plans: why is patient preference information needed?. British Journal of Dermatology, 2021, 185, 882-883.	1.5	0
66	Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.. Journal of Clinical Oncology, 2014, 32, 117-117.	1.6	0